High-growth Platform Future Fields presents a scalable biomanufacturing platform using the EntoEngine and Instar 1.0, offering high output and potential for long-term partnerships with biopharma, agriculture, and food-tech players seeking reliable, cost-effective protein production.

CDMO Expansion With a CDMO service launched in 2023 and a modern production facility in Edmonton (ISO cleanrooms), there is a clear opportunity to upsell contract development and manufacturing services to biotech startups and established firms seeking alternative production routes for complex proteins.

AI Protein Pipeline Ongoing collaboration around AI-engineered proteins via Protein Evolution signals a market for jointly developed, AI-optimized biomolecules, appealing to clients pursuing next-generation therapeutics, enzymes, and specialty proteins.

Sustainability Advantage Green credentials (My Green Lab, 1% for the Planet, UN Global Compact) can be leveraged to target brands and researchers prioritizing sustainable supply chains, enabling co-developed sustainable protein production programs.

Global Growth Signals Recent Series A funding and rapid scale-up indicate investor confidence and expanding capacity; target collaborations with life sciences, agriculture, and food innovation firms looking for scalable, cost-efficient protein expression and rapid prototyping.